Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Eli Lilly and Company reported strong Q2 2024 earnings with revenues up 36% year-on-year, exceeding expectations. Guidance for 2024 was raised by ~$3bn with expectations of $45.4bn — $46.6bn in revenues and EPS of $15.1 — $15.6 on a GAAP basis. Tirzepatide, a key revenue contributor, shows enormous potential in the diabetes and weight loss markets, driving Lilly's share price and market cap valuation.

Eli Lilly Q2 Earnings: Thanks To Tirzepatide, $1 Trillion Valuation Now In Sight

Review Lilly's (LLY) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

International Markets and Lilly (LLY): A Deep Dive for Investors

Holding a promising future due to recent success in the obesity drug market, Eli Lilly (NYSE:LLY) appears to be bound for continued gains.

Is Eli Lilly a Stock To Buy and Hold Forever?

CarGurus

CleanSpark

Hyatt Hotels

Hillenbrand

Robinhood

PureCycle Technologies

Plug Power

Triumph Group

Trade Desk

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Eli Lilly To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Monday

Eli Lilly and Company triggered a Buy signal after a price pop from the latest earnings report. Technical Buy signals, including Full Stochastic and MACD crossover, indicate upward momentum and potential test of the recent high in price. Portfolio managers may need to sell Eli Lilly stock due to high exposure, potentially slowing bounce in a bear market.

Eli Lilly Triggers Our Confirmed Buy Signal (Technical Analysis)

Pfizer

The recent sell-off brought biopharma stocks down by a bit. Nothing has changed about their ability to compete.

Prediction: Buying Biotech and Pharma Stocks During This Sell-Off Will Be a Smart Move

Morphic Holding Inc

NEW YORK, NY / ACCESSWIRE / August 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lilly") (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.

MORF INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Clients to Contact the Firm!

Biogen

A blood test that checks for an abnormal protein could detect 90% of Alzheimer's cases. Eli Lilly recently obtained approval for an early Alzheimer's treatment, Kisunla.

A Blood Test Could Detect Early Alzheimer's. That Could Make These 2 Stocks Red-Hot Buys.

Costco

Ralph Lauren

Despite the volatility seen this summer, certain stocks are managing to outperform the broader market. Strong second-quarter financial results and positive forward guidance have propelled some stocks ahead of their peers and are leading to big gains for their shareholders.

3 Stocks to Load-Up On Before Autumn Arrives

Apple

Disney

The Score is a weekly review of the biggest stock moves and the news that drove them.

The Score: Apple, Walt Disney, Eli Lilly and More Stocks That Defined the Week

Eli Lilly And Co LLY reported on Thursday second-quarter revenue of $11.3 billion, up 36% year-over-year, easily surpassing the consensus of $9.95 billion.

Eli Lilly's Q2 Sales Surge 36%, Analysts Cautious On Future Supply, Market Dynamics; Optimistic About Next-Gen Oral Weight-Loss Drug

Investors of Eli Lilly (LLY) continued to ride the wave created by the pharmaceutical firm's powerhouse second-quarter earnings report.

Eli Lilly Stock Keeps Climbing After Drugmaker's Strong Earnings Report

Taiwan Semiconductor Manufacturing

Long-term stocks, or those that are meant to be held for over a year, let investors ignore daily market fluctuations.

3 Dynamite Stocks to Load Up On For the Next Major Bull Market Rally

Ensign Group

McKesson

The stock market is currently in a rotation. Traders are moving capital from aggressive growth and technology names to find safety in other sectors of the market.

3 Healthcare Stocks to Sell in August Before They Crash & Burn

NEW YORK, NY / ACCESSWIRE / August 9, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lilly") (NYSE:LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.

MORF SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Shareholders to Contact the Firm Today!

We're nearing the end of second-quarter earnings season, so this is a good moment to screen the S&P 500 and show which companies increased revenue the most while also improving their profit margins.

These stocks join Meta and Eli Lilly as the biggest winners this earnings season

Novo Nordisk had a big head start in the race to dominate the weight-loss market. But Eli Lilly LLY 5.53%increase; green up pointing triangle is catching up fast.

Eli Lilly Is Gaining on Novo Nordisk in the Obesity Race

Novo Nordisk

Obesity drugmakers like Eli Lilly NYSE: LLY and Novo Nordisk NYSE: NVO were not immune to the broad market sell-off sparked by the June CPI report, but investors looking to get into these names should be cheering. The stocks are down 20% or more from their highs, offering big discounts and the opportunity for fat profits over the long term.

It's Too Soon to Buy the Dip in Weight Loss Drugmakers

Johnson & Johnson

Eli Lilly is a leader in diabetes and obesity care, but it's also making progress elsewhere. Johnson & Johnson has a robust underlying business, and a rare and ongoing dividend streak.

2 Healthcare Stocks to Buy Hand Over Fist in August

CNBC's Jim Cramer on Thursday recommended that investors not base portfolio decisions solely off of macro economic trends, like new employment data or interest rates. He discussed pharmaceutical giant Eli Lilly's blow-out quarter, saying its success is not due to general attitudes on the market.

After Eli Lilly's blowout quarter, Cramer says not to get too caught up in macro market trends

Major U.S. equities indexes rallied after jobless claims data released Thursday helped ease worries about the economy. The S&P 500 jumped 2.3%, marking the strongest daily performance for the benchmark index since November 2022.

S&P 500 Gains and Losses Today: Eli Lilly Soars on Growing Demand for Weight-Loss Drugs

Eli Lilly (LLY) shares soared Thursday, after the company's second-quarter earnings surpassed expectations on booming demand for its weight-loss drugs and executives provided updates on production capacity and more.

4 Key Takeaways From Eli Lilly's Earnings

Eli Lilly and Company (NYSE:LLY ) Q2 2024 Results Conference Call August 8, 2024 11:30 AM ET Company Participants Joe Fletcher - Senior Vice President-Investor Relations Dave Ricks - Chief Executive Officer Gordon Brooks - Group VP, Controller & Corporate Strategy and Interim CFO Dan Skovronsky - Chief Scientific Officer and President-Lilly Immunology Patrik Jonsson - President-Lilly Diabetes and Obesity and Lilly USA Ilya Yuffa - Executive Vice President Conference Call Participants Seamus Fernandez - Guggenheim Terence Flynn - Morgan Stanley Chris Schott - JPMorgan Tim Anderson - Wolfe Research Umer Raffat - Evercore Mohit Bansal - Wells Fargo Alex Hammond - Bank of America Evan Seigerman - BMO Capital Markets David Risinger - Leerink Partners Kerry Holford - Berenberg Chris Shibutani - Goldman Sachs Akash Tewari - Jefferies Trung Huynh - UBS Steve Scala - TD Cowen Louise Chen - Cantor Operator Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q2 2024 Earnings Call. [Operator Instructions].

Eli Lilly and Company (LLY) Q2 2024 Earnings Call Transcript

NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. (“Morphic”) (NASDAQ: MORF) and Eli Lilly and Company (“Eli Lilly”) (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.

Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses

Eli Lilly ( LLY ) reported strong quarterly results on Thursaday morning, with revenue increasing 36%, driven primarily by the success of Mounjaro, Zepbound, and Verzenio. The company also saw a significant increase in earnings per share (EPS), up 68% year-on-year and eclipsing analysts' estimates by 42%.

News for Eli Lilly Stock (LLY)